Clinical trial
A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA)
NCT04973280 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA)
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 26, 2021
- Completion date
- July 21, 2022
- Enrollment
- 187 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.